Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang, Aya Abdelnaser, Alexander J Haas, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Iscience
|
December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
European Urology Oncology
|
May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
María Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Pasquale Rescigno, Nuria Porta, Laura Finneran, et al.
Journal for Immunotherapy of Cancer
|
June 18, 2022
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, et al.
Cancer Cell
|
March 3, 2023
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Nicolò Bancaro, Bianca Calì, Martina Troiani, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang, Aya Abdelnaser, Alexander J Haas, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Iscience
|
December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
European Urology Oncology
|
May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
María Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Pasquale Rescigno, Nuria Porta, Laura Finneran, et al.
Journal for Immunotherapy of Cancer
|
June 18, 2022
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, et al.
Cancer Cell
|
March 3, 2023
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Nicolò Bancaro, Bianca Calì, Martina Troiani, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Page
of 8